Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Drugs Used in Lower Respiratory Disorders: Overview

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Atypical Pneumonia

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Functional disruptions of the brain network in low back pain: a graph-theoretical study.

Neuroradiology·2023

Same author

Probiotics for preventing acute upper respiratory tract infections.

The Cochrane database of systematic reviews·2022

Same author

Thrombolytic therapy for pulmonary embolism.

The Cochrane database of systematic reviews·2021

Same author

Potassium channel Shaker play a protective role against cardiac aging in Drosophila.

Yi chuan = Hereditas·2021

Same author

Thrombolytic therapy for pulmonary embolism.

The Cochrane database of systematic reviews·2018

Same author

Serum levels of immunoglobulins in an adult population and their relationship with nonalcoholic fatty liver disease.

Journal of digestive diseases·2018

Search research articles

Related Experiment Video

Updated: Apr 18, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Macrolides for diffuse panbronchiolitis.

Xiufang Lin¹, Jing Lu, Ming Yang

¹Center of Geriatrics and Gerontology, West China Hospital, Sichuan University, Chengdu, China.

The Cochrane Database of Systematic Reviews

|January 26, 2015

Summary

This summary is machine-generated.

Limited evidence supports macrolide antibiotics for diffuse panbronchiolitis (DPB). One small trial showed potential benefits, but more high-quality research is needed to confirm macrolide efficacy for DPB treatment.

More Related Videos

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

Related Experiment Videos

Last Updated: Apr 18, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

Area of Science:

Respiratory Medicine
Pharmacology

Background:

Diffuse panbronchiolitis (DPB) is a chronic airway disease prevalent in East Asian populations.
Macrolide antibiotics are a primary treatment for DPB, supported by limited retrospective and non-randomized studies.

Purpose of the Study:

To evaluate the efficacy and safety of macrolide antibiotics in treating diffuse panbronchiolitis (DPB).

Main Methods:

Systematic review and meta-analysis of randomized controlled trials (RCTs) and quasi-RCTs.
Searched multiple databases including CENTRAL, MEDLINE, EMBASE, CBM, CNKI, KoreaMed, and Japana Centra Revuo Medicina up to July 2014.
Assessed study quality and risk of bias; primary outcomes included five-year survival, lung function, and clinical response.

Main Results:

Included only one RCT with 19 participants and significant methodological limitations.
The RCT indicated improvement in computerized tomography images for all participants receiving long-term, low-dose erythromycin compared to controls.
No adverse effects were reported in the included trial; no new trials were identified for this 2014 update.

Conclusions:

Current evidence for macrolide efficacy in DPB treatment is minimal.
No new treatment recommendations can be made due to limited high-quality data.
Current guidelines suggest low-dose macrolides for at least six months post-diagnosis may be reasonable.